Safety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma

This study will test whether anti-EBV autologous TCR-T cell injection is safe and effective for patients with relapsed or refractory EBV-positive lymphoma who have HLA-A11:01. Researchers will look at safety, tolerability, and the maximum tolerated dose or recommended dose for future studies. The study will also measure how the infused TCR-T cells expand and persist in the body, changes in EBV DNA levels and T-cell subgroups in the blood, and whether the treatment shows early signs of clinical benefit. Researchers will also explore whether the treatment causes an immune response against the infused cells.

NCT Number	NCT07162012
Lead Sponsor	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Conditions	NK/T-cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), DLBCL
Enrollment	24 participants
Start Date	2025-09-20
Primary Completion	2028-09 (estimated)
Study Completion	2029-09 (estimated)
Updated on ClinicalTrials.gov	2025-12-02